Browse by author
Lookup NU author(s): Professor Nick ReynoldsORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2017 British Association of Dermatologists. Background: Evidence of the comparative effectiveness of biological therapies for psoriasis on health-related quality of life (HRQoL) in routine clinical practice is limited. Objectives: To examine the comparative effectiveness of adalimumab, etanercept and ustekinumab on HRQoL in patients with psoriasis, and to identify potential predictors for improved HRQoL. Methods: This was a prospective cohort study in which changes in HRQoL were assessed using the Dermatology Life Quality Index (DLQI) and EuroQoL-5D (EQ-5D) at 6 and 12 months. Multivariable regression models were developed to identify factors associated with achieving a DLQI of 0/1 and improvements in the EQ-5D utility score. Results: In total, 2152 patients with psoriasis were included, with 1239 patients on adalimumab, 517 on etanercept and 396 on ustekinumab; 81% were biologic naïve. For the entire cohort, the median (interquartile range) DLQI and EQ-5D improved from 18 (13-24) and 0·73 (0·69-0·80) at baseline to 2 (0-7) and 0·85 (0·69-1·00) at 6 months, respectively (P < 0·001). Similar improvements were achieved at 12 months. At 12 months, multivariable regression modelling showed that female sex, multiple comorbidities, smoking and a higher DLQI or a lower EQ-5D utility score at baseline predicted a lower likelihood of achieving a DLQI of 0/1 or improvement in the EQ-5D. Compared with adalimumab, patients receiving etanercept, but not ustekinumab, were less likely to achieve a DLQI of 0/1. There was no significant difference between the biological therapies in EQ-5D improvement. Conclusions: In routine clinical practice biological therapies produce marked improvement in HRQoL, which is influenced by the choice of biological therapy, baseline impairment in HRQoL, lifestyle characteristics and comorbidities. These findings should help inform selection of optimal biological therapy for patients related to improvements in HRQoL.
Author(s): Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, Mcelhone K, Smith CH, Reynolds NJ, Griffiths CEM
Publication type: Article
Publication status: Published
Journal: British Journal of Dermatology
Year: 2017
Volume: 177
Issue: 5
Pages: 1410-1421
Print publication date: 01/11/2017
Online publication date: 30/03/2017
Acceptance date: 23/03/2017
ISSN (print): 0007-0963
ISSN (electronic): 1365-2133
Publisher: Wiley-Blackwell
URL: https://doi.org/10.1111/bjd.15531
DOI: 10.1111/bjd.15531
Altmetrics provided by Altmetric
